The highly leukemogenic avian retrovirus E26 contains two oncogenes, v-Myb and v-Ets, which are expressed together as a fusion protein. The cellular homolog of v-Myb, designated c-Myb, encodes a transcription factor. Deletion or disruption of a negative regulatory domain mapping within the carboxy-terminal domain of c-Myb results in enhanced transactivating capacity and in parallel, leads to activation of its ability to transform hemopoietic cells. c-Myb is expressed preferentially, but not exclusively, in immature hemopoietic cells and its expression decreases as cells differentiate.
Host
Mouse
Immunogen
A synthetic peptide, corresponding to aa 119-135 (RRKVEQEGYPQESSKAG) of c-myb oncoprotein, coupled to KLH
Isotype
IgG1 Kappa
Positive Control
Jurkat, MOLT-4, COLO or BT-20 cells. Colon or breast carcinomas.
Reactivity
Human
Recombinant
FALSE
Regulatory
RUO
Swissprot
P01104
Uniprot
606320
Gene Id
4602
Buffer
200μg/ml of Ab purified from Bioreactor Concentrate by Protein A/G. Prepared in 10mM PBS with 0.05% BSA; 0.05% azide. Also available WITHOUT BSA; azide at 1.0mg/ml.
Concentration
1.0mg/ml
Description
There are no warranties, expressed or implied, which extend beyond this description. Company is not liable for any personal injury or economic loss resulting from this product.
Purity
Purified Ab WITHOUT BSA and Azide at 1.0mg/ml
Applications
FACS, IF
Description
Optimal dilution for a specific application should be determined., FACS ; IF
Dilution
FACS
0.5-1μg/million cells in 0.1ml
IF
1-2μg/ml
Reviews of Anti-c-Myb Oncoprotein Antibody BHA10203571